Results 41 to 50 of about 7,838 (234)

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data

Clinical Pharmacokinetics, 2021
Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control.
J. Leohr, M. Dellva, K. Carter, E. Labell, H. Linnebjerg   +4 more
semanticscholar   +1 more source

Meeting of the expert committee on the use of pre-mixed insulin preparation Humalog Mix 50 in type 2 diabetes mellitus

Сахарный диабет, 2013
The panel of experts has a held a discussion on effectiveness and tactics of glycemic control by pre-mixed insulin preparations in T2DM. Special attention was paid to the aspects of treatment with Humalog Mix 50, including indications and ...
Editorial team Diabetes Mellitus
doaj   +1 more source

Lispro in the Body

The FASEB Journal, 2021
Lispro is a rapid acting insulin that has been used for keeping blood pressure under control . A rapid acting insulin allows for your body to maintain a balance. This form of insulin is used to treat people with Type 1 and 2 diabetes and keeps your glucose levels from getting too high.
Joaquin Berry, Jaydon Beaver
openaire   +1 more source

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus

Clinical Pharmacokinetics, 2021
This study was performed to satisfy a US Food and Drug Administration post-marketing requirement to compare the dose responses for Technosphere® Insulin (TI; MannKind Corporation, Westlake Village, CA, USA) and subcutaneous insulin lispro (LIS) across a ...
M. Grant, T. Heise, R. Baughman
semanticscholar   +1 more source

Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015

Indian Journal of Endocrinology and Metabolism, 2015
As injectable therapies such as human insulin, insulin analogs, and glucagon-like peptide-1 receptor agonists are used to manage diabetes, correct injection technique is vital for the achievement of glycemic control.
Nikhil Tandon, Sanjay Kalra, Yatan Pal Singh Balhara, Manash P Baruah, Manoj Chadha, Hemraj B Chandalia, Subhankar Chowdhury, Kesavadev Jothydev, Prasanna K. M. Kumar, Madhu S V, Ambrish Mithal, Sonal Modi, Shailesh Pitale, Rakesh Sahay, Rishi Shukla, Annamalai Sundaram, Ambika G Unnikrishnan, Subhash K Wangnoo   +17 more
doaj   +1 more source

Insulin management in hospitalized patients with diabetes mellitus on high-dose glucocorticoids: Management of steroid-exacerbated hyperglycemia.

PLoS ONE, 2021
BackgroundGlucocorticoid (GC)-exacerbated hyperglycemia is prevalent in hospitalized patients with diabetes mellitus (DM) but evidence-based insulin guidelines in inpatient settings are lacking.Methods and findingsRetrospective cohort study with ...
Yu-Chien Cheng, Yannis Guerra, Michael Morkos, Bettina Tahsin, Chioma Onyenwenyi, Louis Fogg, Leon Fogelfeld   +6 more
doaj   +1 more source

The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy [PDF]

, 2014
The discovery of increased formation of methylglyoxal (MG) by cell metabolism in high glucose concentration in vitro suggested possible relevance to diabetes and diabetes complications (1,2).
Rabbani, Naila, Thornalley, Paul J.
core   +1 more source

Two Cases of Allergy to Insulin in Gestational Diabetes [PDF]

Endocrinology and Metabolism, 2015
Allergic reaction to insulin is uncommon since the introduction of human recombinant insulin preparations and is more rare in pregnant than non-pregnant females due to altered immune reaction during pregnancy.
Gi Jun Kim, Shin Bum Kim, Seong Il Jo, Jin Kyeong Shin, Hee Sun Kwon, Heekyung Jeong, Jang Won Son, Seong Su Lee, Sung Rae Kim, Byung Kee Kim, Soon Jib Yoo   +10 more
doaj   +1 more source

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

Diabetes, obesity and metabolism, 2020
To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes in a 26‐week, treat‐to‐target, phase 3 trial.
L. Klaff, D. Cao, M. Dellva, J. Tobian, J. Miura, D. Dahl, Jean Lucas, J. Bue-Valleskey   +7 more
semanticscholar   +1 more source

Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes

Journal of Diabetes Science and Technology, 2022
Background: We evaluated the effect of meloxicam on insulin lispro pharmacokinetics and glucose pharmacodynamics over 10 days of continuous subcutaneous insulin infusion (CSII) at one infusion site in people with type 1 diabetes (T1D). Method: This phase
P. Garhyan, E. Pratt, O. Klein, S. Famulla, E. Zijlstra, Amy LaLonde, Monica R. Swinney, C. Kazda, E. Dassau   +8 more
semanticscholar   +1 more source